Navigation Links
Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease
Date:6/8/2011

MOUNTAIN VIEW, Calif., June 8, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed an Expanded Access program to provide EPI-743 to seriously ill patients diagnosed with inherited respiratory chain diseases of the mitochondria. Patients with genetically confirmed disease and patients who meet specific clinical criteria, absent genetic confirmation are both eligible.

As of June 1, 2011, 40 seriously ill subjects diagnosed with genetically confirmed inherited mitochondrial disease have been treated with EPI-743 worldwide for a cumulative exposure of over 7,436 days. No significant drug-related adverse events have been observed. Initial clinical, biomarker, and brain-imaging data are encouraging. The company cautions that the data obtained in these initial studies is preliminary and needs verification in controlled prospective trials. Edison and its clinical investigator team are working closely with FDA and the European Medicines Agency to expedite prospective phase 2B/3 clinical trials. EPI-743 has received orphan designation from FDA.

Clinical Trial Sites

United States

Clinical trial enrollment sites have been established in North America at Lucile Packard Children's Hospital– Stanford University Medical Center; Akron Children's Hospital; Columbia University; Seattle Children's Hospital; Medical University of South Carolina; Children's Hospital of Philadelphia; and University of California, Los Angeles.

Additional trial sites are being established in Europe, Japan, and in North America.

Treatment Information

Edison Pharmaceuticals

— EdisonPharma.com

United Mitochondrial Disease Foundation

— UMDF.org

Friedreich's Ataxia Research Alliance

— CureFA.org

MitoAction

— MitoAction.org

United States Food and Drug A
'/>"/>

SOURCE Edison Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation
2. Samsung Medison Pledges to Become a World-Class Medical Device Company
3. NOMAD by Aribex Receives Edison Best New Product Award
4. Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
5. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
6. Zargis Medical Strikes Gold at 2010 Edison Awards
7. Orthocare Innovations Compas and Smart Pyramid Recognized at Edison Best New Product Awards
8. Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards
9. Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
10. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
11. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 2007 - ImmunoGen, Inc.,(Nasdaq: IMGN), a biopharmaceutical company ... (TAP),technology, today announced that clinical findings for three,different ... are to be,reported at the 43rd American Society ... June 1-5, 2007 in Chicago, IL., Trastuzumab-DM1 (abstract ...
... 2007 - GTx, Inc., (NASDAQ:,GTXI) announced today that ... clinical trial of Ostarine(TM) and from the ongoing ... for the treatment of multiple side effects of ... upcoming 2007,Annual Meeting of the American Society of ...
Cached Medicine Technology:ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... from the University of Melbourne and La Trobe University have ... grains such as wheat and barley. With the stress being ... that this discovery would allow them to manipulate the fibre ... the production of beta-glucans, which is a major part of ...
... is to soon go on Phase I trial. It maybe ... Biocon, Ms.Kiran Mazumdar Shaw. ,Ms.Shaw was speaking ... Foundation(MDRF) on awards for innovation and R&D.// There are close ... to diabetes should always bear this in mind and develop ...
... underwent a successful life-changing operation in India and returned home ... being// overweight. ,David Rogers, 62, from Abbeydale, Worcestershire, ... for the double hip and knee replacements that he desperately ... was about 37 kg too heavy for the surgery. ...
... two new genes found with breast tumors can predict the ... In the report appearing in he April 1 issue of ... identify women at risk for an early relapse of breast ... previously discovered as a potential marker of relapse in hormone-receptor ...
... the peels of fruits and vegetables, which are thrown away ... better to have a second thought next time, when you ... and keeps you young. ,As reported in foodconsumer.org ... the United States to $2.7 billion in 2003. Top of ...
... have bettered among the teenagers and young adults (TYAs) in ... than in those where people have to pay for their ... system of health insurance for all, regardless of age, meant ... than they were in the USA. ,Prof ...
Cached Medicine News:Health News:Overweight Briton Underwent Successful Surgery In India Being Denied By NHS 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 2Health News:Easy Access To Healthcare Services Essential For Better Survival Rates 3
... third-generation immunoassay system combines continuous ... processing with a broad testing ... higher volume clinical laboratories to ... tests simultaneously, as well as ...
... ADVIA Centaur delivers a new ... provides the flexibility to integrate ... now and in the future. ... comprehensive disease-focused menu of immunoassays ...
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
...
Medicine Products: